V
Victor G. Vogel
Researcher at Geisinger Health System
Publications - 158
Citations - 23677
Victor G. Vogel is an academic researcher from Geisinger Health System. The author has contributed to research in topics: Breast cancer & Tamoxifen. The author has an hindex of 49, co-authored 151 publications receiving 22364 citations. Previous affiliations of Victor G. Vogel include MedStar Washington Hospital Center & Geisinger Medical Center.
Papers
More filters
Journal ArticleDOI
Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
TL;DR: Tamoxifen decreases the incidence of invasive and noninvasive breast cancer and its use as a breast cancer preventive agent is appropriate in many women at increased risk for the disease.
Journal ArticleDOI
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
Edward H. Romond,Edith A. Perez,John Bryant,Vera J. Suman,Charles E. Geyer,Nancy E. Davidson,Elizabeth Tan-Chiu,Silvana Martino,Soonmyung Paik,Peter A. Kaufman,Sandra M. Swain,Thomas M. Pisansky,Louis Fehrenbacher,Leila A. Kutteh,Victor G. Vogel,Daniel W. Visscher,Greg Yothers,Robert B. Jenkins,Ann M. Brown,S. R. Dakhil,Eleftherios P. Mamounas,Wilma L. Lingle,Pamela M. Klein,James N. Ingle,Norman Wolmark +24 more
TL;DR: Tastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide improves outcomes among women with surgically removed HER2-positive breast cancer.
Journal ArticleDOI
Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
Priya Rastogi,Stewart J. Anderson,Harry D. Bear,Charles E. Geyer,Morton S. Kahlenberg,André Robidoux,Richard G. Margolese,James L. Hoehn,Victor G. Vogel,Shaker R. Dakhil,Deimante Tamkus,Karen M. King,Eduardo R. Pajon,Mary Johanna Wright,Jean Robert,Soonmyung Paik,Eleftherios P. Mamounas,Norman Wolmark +17 more
TL;DR: B-18 and B-27 demonstrate that preoperative therapy is equivalent to adjuvant therapy and showed that the addition of preoperative taxanes to AC improves response.
Journal ArticleDOI
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
Victor G. Vogel,Joseph P. Costantino,D. Lawrence Wickerham,D. Lawrence Wickerham,Walter M. Cronin,Reena S. Cecchini,James N. Atkins,Therese B. Bevers,Louis Fehrenbacher,James L. Wade,Richard G. Margolese,Scott M. Lippman,Carolyn D. Runowicz,Patricia A. Ganz,Steven E. Reis,Leslie G. Ford,V. Craig Jordan,Norman Wolmark +17 more
TL;DR: Raloxifene is as effective as tamoxifen in reducing the risk of invasive breast cancer and has a lower risk of thromboembolic events and cataracts but a nonstatistically significant higher risk of noninvasive breast cancer.
Journal ArticleDOI
Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer: NSABP B-31
Elizabeth Tan-Chiu,Greg Yothers,Edward H. Romond,Charles E. Geyer,Michael S. Ewer,Deborah Keefe,Richard P. Shannon,Sandra M. Swain,Ann M. Brown,Louis Fehrenbacher,Victor G. Vogel,Thomas E. Seay,Priya Rastogi,Eleftherios P. Mamounas,Norman Wolmark,John Bryant +15 more
TL;DR: Administering trastuzumab with paclitaxel after AC increases incidence of congestive heart failure and lesser CD, and potential cardiotoxicity should be carefully considered when discussing benefits and risks of this therapy.